IP Library Granted Patent US 10,233,421
Granted Patent B2
US 10,233,421 · App. 15/457,893 · Granted Mar 19, 2019

Differentiation of pluripotent stem cells

Inventors: Janet Davis (Skillman, NJ); Jiajian Liu (Skillman, NJ); Christine Parmenter (Skillman, NJ); Pascal Ghislain Andre Bonnet (Beerse, BE)
Assignee: Janssen Biotech, Inc.
C12N5/0606C12N5/0678C12N2501/11C12N2501/119C12N2501/135C12N2501/16C12N2501/165C12N2501/19C12N2501/999C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,233,421
App. No.
15/457,893
Granted
Mar 19, 2019
Kind
B2
Abstract

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

Claims (14)

1. A method to differentiate pluripotent stem cells into definitive endoderm cells comprising culturing the pluripotent stem cells with a medium supplemented with activin A, Wnt3a, 5-chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜] tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one and one or more of EGF and FGF4.

2. The method of claim 1 , wherein the medium is supplemented with activin A, Wnt3a, 5-chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜] tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one and EGF.

3. The method of claim 1 , wherein the medium is supplemented with activin A, Wnt3a, 5-chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1-14,18˜] tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one and FGF-4.

4. The method of claim 1 , wherein the medium is supplemented with activin A, Wnt3a, 5-chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜] tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one EGF and FGF-4.

5. The method of claim 4 , wherein the medium is further supplemented with PDGF-AB.

6. The method of claim 5 wherein the medium is further supplemented with VEGF.

7. The method of claim 4 , wherein the medium is further supplemented with GDF-8 and muscimol.

8. The method of claim 4 , wherein the medium is further supplemented with PDFG-A, VEGF, PDGF, muscimol and GDF-8.

9. The method of claim 1 , wherein the pluripotent stem cells are human pluripotent stem cells.

10. The method of claim 9 , wherein the human pluripotent stem cells are human embryonic stem cells.

11. A method to differentiate pluripotent stem cells into definitive endoderm cells comprising culturing the pluripotent stem cells with a medium supplemented with activin A and 5-chloro-1,8,10,12,16,22,26,32-octaazapentacyclo[24.2.2.1˜3,7˜.1˜9,13˜.1˜14,18˜] tritriaconta-3(33),4,6,9(32),10,12,14(31),15,17-nonaen-23-one.

12. The method of claim 11 , wherein the medium is further supplemented with Wnt3a.

13. The method of claim 11 , wherein the pluripotent stem cells are human pluripotent stem cells.

14. The method of claim 13 , wherein the human pluripotent stem cells are human embryonic stem cells.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 047903 FRAME: 0496. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 15, 2023
From: LIU, JIAJIAN
To: CENTOCOR ORTHO BIOTECH, INC.
Reel/Frame 065773/0587 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE CONVEYING PARTY PREVIOUSLY RECORDED ON REEL 049890 FRAME 0869. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Oct 15, 2023
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 065238/0852 →
CHANGE OF NAME Recorded Jan 4, 2019
From: CENTOCOR BIOTECH, INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 049890/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: LIU, JIAJIAN
To: CENTOCOR BIOTECH, INC.
Reel/Frame 047903/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: DAVIS, JANET E.
To: JANSSEN BIOTECH, INC.
Reel/Frame 047776/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: PARMENTER, CHRISTINE
To: JANSSEN BIOTECH, INC.
Reel/Frame 047776/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: BONNET, PASCAL
To: JANSSEN BIOTECH, INC.
Reel/Frame 047776/0114 →
Continuity (6)
Continuation 13434409 · Mar 29, 2012
Continuation 12494789 · Jun 30, 2009
Provisional Application 61076900 · Jun 30, 2008
Provisional Application 61076908 · Jun 30, 2008
Provisional Application 61076915 · Jun 30, 2008
Related Publication 20170183625A1 · Jun 29, 2017